About PD Brief
Parkinson's research is moving faster than at any point in its history. Very little of that reaches the people it is actually about.
The findings are published in journals that cost money to read, written in language built for other specialists. What escapes into the wider world usually arrives as a headline — breakthrough, cure within reach, hope for millions — that overstates a small study and leaves out everything needed to judge it. Somewhere between an inaccessible paper and a misleading headline, there should be an honest account of what was actually found.
That is what this is.
What PD Brief does
Every week, we read newly published Parkinson's research and write up one or two studies in plain language. Each issue explains what the researchers set out to learn, what they did, what they found, why it matters, and — the part most coverage skips — what the study does not tell us.
Issues take about five to ten minutes to read. No scientific background is assumed. Technical terms are explained where they appear, and every one of them is collected in the glossary.
Who this is for
Anyone who wants to follow Parkinson's research without a medical degree:
- People living with Parkinson's, who have a direct stake in where the research is going
- Family members and caregivers, who often end up doing the reading
- Students and early researchers looking for a way into an unfamiliar literature
- Clinicians and allied health professionals who want a quick orientation outside their specialty
- Anyone curious about how medical knowledge actually accumulates
How studies are chosen
There are far more Parkinson's papers published each week than could be covered. Selection favours studies that:
- report an original finding rather than restating existing knowledge
- come from peer-reviewed journals, with preprints clearly labelled when included
- would genuinely change how someone understands the field
- are large or rigorous enough that the finding is likely to hold
Negative results are covered deliberately. A well-run trial showing that a promising treatment does not work is as important as one showing that it does, and it is far less likely to be reported anywhere else.
Editorial policy
Independence. PD Brief is not affiliated with any journal, university, pharmaceutical company, patient organisation, or funder. Nobody pays for coverage. Nobody sees an issue before it is published.
Honesty about uncertainty. Most research findings are provisional. Issues say how confident anyone should be, and every issue includes a section on what the study does not establish.
No medical advice. PD Brief explains research. It does not recommend treatments, and nothing in it should be used to make decisions about anyone's care. Those conversations belong with your neurologist.
Corrections. Mistakes will happen. When one is found, the issue is corrected and the correction is noted at the bottom of that issue rather than quietly edited away.
Credit. Every issue links to the original paper, with authors, journal, and DOI. The findings belong to the researchers who did the work. This publication only translates them.
Limits worth stating
This is a summary, not a substitute. A 1,200-word account of a study cannot carry everything the original does, and the choice of what to leave out is a judgement made by a person who can get it wrong.
Anyone who wants to check the reasoning should follow the links to the source papers. Abstracts are almost always free to read, and many papers now are too.
Get in touch
Corrections, questions, and suggestions for studies to cover are all welcome. The quickest way to reach us is the questions page, which is read by the editor. Corrections are published on the issue they concern.